ImmunityBio, Inc.

ImmunityBio is a vertically integrated biotechnology company that focuses on developing next-generation therapies and vaccines designed to strengthen the body's natural immune system. Their primary focus is on tackling cancer and infectious diseases, with a goal of creating long-lasting, safe, and effective treatments that go beyond traditional methods. They leverage a range of immunotherapy and cell therapy platforms, including natural killer (NK) cells, interleukin-15 (IL-15) superagonists, and adenovirus vectors, to activate and sustain immune responses. A key product, ANKTIVA, has received FDA Breakthrough Therapy designation and approval for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).

ImmunityBio aims to be a leader in developing and commercializing immunotherapies and vaccines that address unmet medical needs. They are committed to expanding their clinical trial programs, pursuing regulatory approvals, and increasing access to their therapies. The company emphasizes diversity in their clinical trials and strives to make their treatments available to a wider range of patients, including those in underserved communities.

ImmunityBio offers a range of benefits to employees, including financial benefits such as equity in the business and bonuses, as well as medical, dental, and vision plans. They also provide discounts on various products and services through Benefithub.com, as well as access to legal services, additional life and disability insurance opportunities, and even pet insurance.

ImmunityBio offers a competitive benefits package that includes equity in the business, performance-based bonuses, multiple medical plan options with hundreds of providers and prescription drug discounts, dental and vision plan options, flexible spending accounts, life insurance, and retirement planning services. In addition, employees can access discounts on thousands of brand products through Benefithub.com, and voluntary benefits such as legal services, additional life and disability insurance opportunities, and even pet insurance.

ImmunityBio is a biotechnology company dedicated to developing next-generation therapies and vaccines that strengthen the natural immune system to fight cancers and infectious diseases. Their approach focuses on harnessing the power of the innate immune system, specifically by activating natural killer cells (NK) and T cells, to achieve durable and safe protection against disease. Their mission is to create treatments that are more effective, accessible, and easily administered than current standards of care, ultimately outsmarting diseases like cancer and infectious diseases such as HIV and tuberculosis.

ImmunityBio promotes a culture that prioritizes patient well-being and fosters a collaborative environment. They emphasize the importance of highly skilled and talented individuals working together to develop innovative and safe therapies for difficult diseases. The company is driven by a strong sense of purpose and a commitment to improving the lives of patients worldwide. They encourage a fast-paced and collaborative work environment where employees have diverse opportunities for career growth and a direct stake in the company's success.

ImmunityBio is committed to maximizing diversity and inclusion in its clinical trials by reaching out to and considering participants who represent all people and experiences. The company is striving to change the paradigm of clinical trial participation by making trials more accessible to diverse groups of people, regardless of race, ethnicity, gender identity, sexual orientation, age, physical ability, living conditions, and geographic location. To address the problem of accessibility, the company has trial sites in 31 states, including several in rural locations. ImmunityBio also encourages practitioners to learn about available clinical trials and speak to their patients about the opportunity to enroll in trials appropriate for their condition.